Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.
john_malcolm.ford@novartis.com
John M
JM
Ford
Lisa
L
Rojkjaer
D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D002386:Cataract / Q000139:chemically induced*; D000077588:Deferasirox; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D012107:Research Design; D018401:Sample Size; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000188:drug therapy*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox